"A row between Wes Streeting and pharmaceutical companies has intensified after drugmakers rejected the health secretary's latest offer on NHS drug pricing. Talks broke up without agreement on Friday, meaning the mechanism under which the health service claws back some of the money it pays for medicines will continue at a rate the industry has called unsustainable and says could discourage companies from making investments in the UK."
"The two sides have been in acrimonious negotiations for months after the government unexpectedly raised the rate last December to almost 23% for 2025 for newer medicines. It is understood that Streeting had made an ultimatum that if the industry did not accept his latest generous offer on pricing then the current arrangement would continue unamended and on Friday the Department of Health and Social Care (DHSC) announced talks had broken up with no agreement."
A row between Wes Streeting and pharmaceutical companies intensified after drugmakers rejected the health secretary's latest offer on NHS drug pricing. Talks broke up without agreement, so the VPAG clawback mechanism will continue at a rate the industry calls unsustainable and that could discourage investment in the UK. The government unexpectedly raised the VPAG rate last December to almost 23% for 2025 for newer medicines. Streeting reportedly gave an ultimatum that his generous offer must be accepted or the current arrangement would continue unamended. The ABPI warned the impasse may lead to fewer medicine launches and disadvantage patients. The DHSC said the scheme sustains access and supports taxpayers.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]